{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"}],"units":"Participants"}],"description":"Use of additional immune suppressive agents to treat chronic GVHD other than first line therapy. First line therapy is considered prednisone and tacrolimus/cyclosporin.","groups":[{"description":"All participants in single arm study of CD45RA+ T cell depletion PBSC transplant and Methotrexate and tacrolimus for GVHD prophylaxis that were alive at D100","id":"OG000","title":"Overall Study Patients Alive at D100"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to 5 years","title":"Use of Additional Immune Suppressive Agents to Treat Chronic GVHD","type":"SECONDARY","unitOfMeasure":"Immunosuppressive agents"}